Why meniscus surgery raises your OA risk

After meniscus surgery, many patients are told that osteoarthritis is a realistic long-term consequence — and understandably want to know what that actually means for them. The short answer is that the meniscus does far more than most people realise, and losing part of it sets off a mechanical chain reaction that the joint struggles to compensate for over time.

The meniscus acts as the knee's primary shock absorber, spreading compressive and torsional forces across the tibiofemoral joint surface. When meniscal tissue is removed — whether through partial meniscectomy or total resection — that load is redistributed directly onto the articular cartilage, which is less well equipped to tolerate it. Over years, this concentrated stress drives the cartilage thinning and bony changes characteristic of post-traumatic osteoarthritis (PTOA). Long-term imaging studies tracking patients for 5 to 12 years after arthroscopic partial meniscectomy show progressive radiographic OA changes in the operated knee compared with the unoperated side; total meniscectomy performed in adolescents carries consequences visible at 40-year follow-up. Across this evidence base, meniscal injury and subsequent resection is associated with roughly a 7-fold greater risk of developing knee OA compared with uninjured knees — though individual outcomes vary considerably depending on age, activity level, and the extent of tissue removed.

It is worth noting that repair, where surgically possible, is preferable to resection. However, current surgical techniques do not fully eliminate the PTOA risk: approximately 84% of pre-clinical meniscus repair studies report some improvement over untreated injury, but none achieve complete prevention.

Arthroscopy itself also creates a short-lived window of added cartilage vulnerability. During surgery, the knee's natural synovial fluid is disrupted, altering the joint's temperature, osmolarity, and pH. Natural fluid replacement takes at least one week, leaving the cartilage surface less protected in the immediate post-operative period — a factor that informs how and when early interventions such as hyaluronic acid may be considered.

What post-meniscectomy OA feels like — and when to escalate

Recognising early signs matters more than waiting for a dramatic change. Post-meniscectomy PTOA rarely announces itself all at once — it tends to develop gradually over months or years, often beginning as an ache on stairs, stiffness after sitting for prolonged periods, or swelling that appears after activity and settles with rest. Initially, symptoms may be intermittent and easy to attribute to normal post-operative recovery. Over time, however, load intolerance tends to increase, and morning stiffness lasting more than 30 minutes is a common signal that inflammation has become more persistent.

It is important to separate what an X-ray or MRI shows from what a patient actually experiences. Joint space narrowing on imaging confirms structural change but does not, on its own, explain a patient's pain level or function. Asymptomatic changes — including signal abnormality on MRI — are common after meniscal procedures and do not automatically mean the imaging finding is the source of symptoms. A consultant assessment is needed to correlate the two.

When to seek specialist input

• Pain limiting everyday activities such as walking, stairs, or getting up from a chair
• Night pain that disturbs sleep
• Swelling that recurs regularly after normal activity
• Stiffness that does not settle within 30 minutes of waking
• Symptoms that fail to improve with rest and over-the-counter analgesia after several weeks

First-line management before injections are considered

For most patients developing OA symptoms after meniscus surgery, the first months of management are active and purposeful — not a holding pattern. Physiotherapy is the foundation: targeted quadriceps and hip-strengthening exercises reduce the load passing through the tibiofemoral compartment, and the evidence for this approach in post-traumatic knee OA is strong. Consistency matters more than intensity; a supervised programme of 6 to 12 weeks is the appropriate benchmark before considering the next step.

NSAIDs — either oral or topical — can manage inflammation and pain during flares alongside physiotherapy. Topical formulations are generally preferred for older patients or those with gastrointestinal sensitivities, as systemic absorption is lower. Weight management, activity modification, and appropriate footwear are low-risk additions that compound the gains from an exercise programme.

Injections are typically considered at the third tier: when functional impairment persists despite a sustained, consistent trial of these measures. Preserving injections for this stage also protects their efficacy — deploying them earlier, before first-line management has been given a genuine trial, risks normalising an intervention that works best when the joint genuinely needs it.

Which injections are used and what each one does

Four injection types are used across the post-meniscectomy PTOA pathway, each working through a different mechanism and suited to a different stage or clinical picture.

Corticosteroids (triamcinolone, betamethasone, methylprednisolone) damp down inflammation quickly and are the most commonly used option for managing acute pain flares, with relief typically lasting 2–3 months. No single formulation has proven superior to the others for knee OA. In already-degraded cartilage, however, repeated use carries a recognised chondrotoxicity concern — single-dose studies have documented direct cartilage damage — which requires careful clinical judgement when the joint has already been structurally compromised by meniscal loss. This does not make them inappropriate, but it does mean frequency matters.

Hyaluronic acid (viscosupplementation) restores the lubricating properties of synovial fluid, which are progressively lost as OA advances. The disruption to the synovial environment that arthroscopy causes — as described in the opening section — provides a specific rationale for post-operative HA: evidence shows it significantly reduced pain at two weeks after surgery and improved mobility at both two and six weeks. It tends to suit mild-to-moderate OA rather than advanced joint degeneration.

Platelet-rich plasma (PRP) uses a concentration of the patient's own platelets to support anti-inflammatory and tissue-healing pathways. It is used following partial meniscectomy, though long-term efficacy data remain heterogeneous and are still maturing — the biological rationale is well established, but the clinical evidence base is not yet as settled as for the other options.

Arthrosamid, a polyacrylamide hydrogel injected under ultrasound guidance, integrates permanently into the synovial membrane and acts as a mechanical cushion. It does not regenerate cartilage or reverse OA changes, and is positioned as a delay strategy for patients with mild-to-moderate disease rather than a treatment for end-stage joint failure.

Most comparison data for these injections derive from general knee OA trials rather than studies conducted specifically in post-meniscectomy PTOA populations, which limits how precisely the evidence translates to this group.

The 90-day rule — why your last injection timing matters before surgery

If a knee replacement is on the horizon, one practical question comes up regularly: is it safe to have an injection in the meantime? The short answer is yes — but when you have it matters considerably.

A 2022 meta-analysis pooling data from more than 200,000 patients found that any intra-articular injection given within three months of total knee arthroplasty (TKA) raised the risk of periprosthetic joint infection (PJI) — a serious post-operative complication — with a relative risk of 1.26 compared to patients who had not been injected in that window. Beyond the three-month mark, infection risk returned to baseline with no statistically significant elevation.

The absolute numbers from a 2024 study in the Journal of Arthroplasty give a clearer sense of the scale: patients who received a corticosteroid injection within 90 days of TKA had a PJI rate of 1.6%, compared with 0.41% in controls — nearly a fourfold difference in absolute terms. For a complication that can require further surgery, prolonged antibiotic courses, or in the worst cases implant removal, this is a clinically significant gap.

The 90-day gap has become a near-universal minimum standard in pre-operative planning. Some surgeons extend this to six months when longer-acting steroid formulations have been used — methylprednisolone acetate and betamethasone are most commonly cited — as these agents may persist in the joint environment for longer.

One area where the evidence is less settled is whether hyaluronic acid injections carry the same level of risk as corticosteroids within the 90-day window. Most of the available guidelines and meta-analyses pool all intra-articular injections together rather than stratifying by type, so a definitive head-to-head answer is not yet available. Caution applies to both until clearer data emerge.

The practical implication is straightforward: if total knee replacement is being actively discussed or planned, the timing of any injection should be part of that conversation before it is booked.

When injections are no longer enough — deciding on knee replacement

There comes a point in the post-meniscectomy OA journey when injections are no longer providing the interval of relief they once did — and recognising that point clearly is useful preparation for the conversation that follows.

Several clinical signals typically prompt a surgeon to raise knee replacement as a realistic next step: injections that used to hold for two or three months now wearing off within weeks; persistent functional limitation — difficulty with stairs, disturbed sleep from night pain, inability to walk distances that previously posed no difficulty — despite having followed through on physiotherapy and pain management; and imaging consistent with end-stage joint space loss that matches what is being felt day to day. None of these signals in isolation is an automatic trigger, but together they shift the risk-benefit calculation away from further delay.

Total knee replacement is an elective, shared decision in most cases. Patient readiness, activity goals, and overall health all factor into the timing conversation alongside imaging — patients are active participants in that discussion, not passive recipients of a verdict.

One practical point is worth raising early in that process: the 90-day injection-free window described in the previous section runs from the date of surgery, not the date the decision is made. A patient who receives an injection in the weeks between agreeing to proceed and receiving a surgical date may inadvertently push the earliest safe operative slot back by months. Discussing injection history — and planning any further injections around the anticipated surgical timeline — is the most concrete step a patient can take to avoid that delay and keep their risk profile where it should be.